A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers

Epilepsy Research

Volumn 105, Issue 3, 2013, Pages 362-367

  Agarwal, Suresh K ^a,b   Kriel, Robert L ^a,b   Brundage, Richard C ^a,b   Ivaturi, Vijay D ^a,b,c   Cloyd, James C ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Acute repetitive seizures; Diazepam; Intranasal therapy; Out of hospital; Seizure emergencies

Indexed keywords

DIAZEPAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NOSE IRRITATION; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACUTE REPETITIVE SEIZURES; DIAZEPAM; INTRANASAL THERAPY; OUT-OF-HOSPITAL; SEIZURE EMERGENCIES;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIAZEPAM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; YOUNG ADULT;

EID: 84880041754     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.02.018     Document Type: Article

References (21)

1. Anderson M., Tambe P., Sammons H., Mulla H., Cole R., Choonara I. Pharmacokinetics of buccal and intranasal lorazepam in healthy adult volunteers. Eur. J. Clin. Pharmacol. 2012, 68:155-159.
2. Burstein A.H., Modica R., Hatton M., Forrest A., Gengo F.M. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. J. Clin. Pharmacol. 1997, 37:711-718.
3. Cloyd J.C., Lalonde R.L., Beniak T.E., Novack G.D. A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. Epilepsia 1998, 39:520-526.
4. Dalby N.O., Mody I. The process of epileptogenesis: a pathophysiological approach. Curr. Opin. Neurol. 2001, 14:187-192.
5. Dale O., Nilsen T., Loftsson T., Hjorth Tønnesen H., Klepstad P., Kaasa S., Holand T., Djupesland P.G. Intranasal midazolam: a comparison of two delivery devices in human volunteers. J. Pharm. Pharmacol. 2006, 58:1311-1318.
6. Hardmeier M., Zimmermann R., Rüegg S., Pflüger M., Deuster S., Suter K., Donzelli M., Drewe J., Krähenbühl S., Fuhr P., Haschke M. Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. Clin. Pharmacol. Ther. 2012, 91:856-862.
7. Haschke M., Suter K., Hofmann S., Witschi R., Fröhlich J., Imanidis G., Drewe J., Briellmann T.A., Dussy F.E., Krähenbühl S., Surber C. Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. Br. J. Clin. Pharmacol. 2010, 69:607-616.
8. Ivaturi V.D., Riss J.R., Kriel R.L., Siegel R.A., Cloyd J.C. Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. Epilepsy Res. 2009, 84:120-126.
9. Kälviäinen R., Eriksson K., Häppölä O., Keränen T., Kurola J., Kuusela A.-L., Laukkala T., Ruokonen E., Salmi T., Hirsso P., Kotila M. Update on current care guidelines, the treatment of status epilepticus. Duodecim 2009, 125:2469-2471.
10. Knoester P.D., Jonker D.M., Van Der Hoeven R.T.M., Vermeij T.A.C., Edelbroek P.M., Brekelmans G.J., de Haan G.J. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br. J. Clin. Pharmacol. 2002, 53:501-507.
11. Kriel R.L., Cloyd J.C., Hadsall R.S., Carlson A.M., Floren K.L., Jones-Saete C.M. Home use of rectal diazepam for cluster and prolonged seizures: efficacy, adverse reactions, quality of life, and cost analysis. Pediatr. Neurol. 1991, 7:13-17.
12. Lau S.W.J., Slattery J.T. Absorption of diazepam and lorazepam following intranasal administration. Int. J. Pharm. 1989, 54:171-174.
13. Lowenstein D.H., Alldredge B.K. Status epilepticus. N. Engl. J. Med. 1998, 338:970-976.
14. Lowenstein D.H., Bleck T., Macdonald R.L. It's time to revise the definition of status epilepticus. Epilepsia 1999, 40:120-122.
15. Milligan N., Dhillon S., Oxley J., Richens A. Absorption of diazepam from the rectum and its effect on interictal spikes in the EEG. Epilepsia 1982, 23:323-331.
16. Shinnar S., Hesdorffer D.C., Nordli D.R., Pellock J.M., O'Dell C., Lewis D.V., Frank L.M., Moshé S.L., Epstein L.G., Marmarou A., Bagiella E. Phenomenology of prolonged febrile seizures: results of the FEBSTAT study. Neurology 2008, 71:170-176.
17. Veldhorst-Janssen N.M.L., Fiddelers A.A.A., van der Kuy P.-H.M., Theunissen H.M.S., de Krom M.C.T.F.M., Neef C., Marcus M.A.E. Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. Clin. Ther. 2011, 33:2022-2028.
18. Wermeling D.P., Miller J.L., Archer S.M., Manaligod J.M., Rudy A.C. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J. Clin. Pharmacol. 2001, 41:1225-1231.
19. Wermeling D.P., Record K.A., Archer S.M., Rudy A.C. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. Epilepsy Res. 2009, 83:124-132.
20. Wermeling D.P., Record K.A., Kelly T.H., Archer S.M., Clinch T., Rudy A.C. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. Anesth. Analg. 2006, 103:344-349. table of contents.
21. Working Group on Status Epilepticus Treatment of convulsive status epilepticus, recommendations of the epilepsy foundation of America's working group on status epilepticus. J. Am. Med. Assoc. 1993, 270:854-859.